Medindia LOGIN REGISTER
Medindia
Advertisement

PharmAthene to Host Second Quarter 2008 Conference Call and Webcast on Tuesday, August 12, 2008

Wednesday, August 6, 2008 General News
Advertisement
ANNAPOLIS, Md., Aug. 5 PharmAthene, Inc.(Amex: PIP) a biodefense company developing medical countermeasures againstbiological and chemical threats, announced today that its financial resultsfor the second quarter of 2008 will be released on Tuesday, August 12, 2008.
Advertisement

PharmAthene management will be hosting a conference call to discuss itssecond quarter 2008 financial results. The call is scheduled to begin at 4:30p.m. Eastern Time on Tuesday, August 12, 2008 and will last approximately 45minutes.
Advertisement

The dial-in number within the United States is 800-706-7741. The dial-innumber for international callers is 617-614-3471. The participant passcode is48062719.

A replay of the conference call will be available for 30 days, beginningat approximately 6:30 p.m. Eastern Time on August 12, 2008 until approximately11:50 p.m. Eastern Time September 9, 2008. The dial-in number from within theUnited States is 888-286-8010. For international callers, the dial-in numberis 617-801-6888. The participant passcode is 76313724.

The conference call will also be webcast and can be accessed from thecompany's website at www.pharmathene.com. A link to the webcast may be foundunder the Investor Relations section of the website. The webcast will beavailable for 30 days, or until approximately September 9, 2008.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States andits allies by developing and commercializing medical countermeasures againstbiological and chemical weapons. PharmAthene's lead product developmentprograms include (1) SparVax(TM) -- a second generation recombinant protectiveantigen (rPA) anthrax vaccine, (2) Valortim(TM) -- a fully human monoclonalantibody for the prevention and treatment of anthrax infection, (3)Protexia(R) -- a novel bioscavenger for the prevention and treatment ofmorbidity and mortality associated with exposure to chemical nerve agents, (4)RypVax(TM) -- a recombinant dual antigen vaccine for plague, and (5) a thirdgeneration rPA anthrax vaccine. For more information about PharmAthene, pleasevisit www.PharmAthene.com.

SOURCE PharmAthene, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close